These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 20332752)

  • 1. Imatinib: high dose versus standard dose.
    Jabbour E
    Clin Adv Hematol Oncol; 2009 Dec; 7(12):812-4. PubMed ID: 20332752
    [No Abstract]   [Full Text] [Related]  

  • 2. Investigator profile. Brian J. Druker, M.D. Interview by Vicki P. Glaser.
    Druker BJ
    J Hematother Stem Cell Res; 2001 Dec; 10(6):721-4. PubMed ID: 11798498
    [No Abstract]   [Full Text] [Related]  

  • 3. Position paper on imatinib mesylate in chronic myeloid leukaemia.
    O'Brien SG; Rule SA
    Br J Haematol; 2002 Oct; 119(1):268-72. PubMed ID: 12358935
    [No Abstract]   [Full Text] [Related]  

  • 4. New agent overcomes resistance to imatinib.
    Ahmad K
    Lancet Oncol; 2005 Mar; 6(3):137. PubMed ID: 15759363
    [No Abstract]   [Full Text] [Related]  

  • 5. Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia.
    Milojkovic D; Short K; Salisbury JR; Creamer D; du Vivier AW; Mufti GJ
    Leukemia; 2003 Jul; 17(7):1414-6. PubMed ID: 12835733
    [No Abstract]   [Full Text] [Related]  

  • 6. Response to the case report by Mattar: Generic Imatinib (Imatib, Cipla) in a patient with chronic myeloid leukemia in chronic phase.
    Gogtay J; Chahchad S; Jadhav S; Purandare S
    Int J Hematol; 2010 Dec; 92(5):772-3. PubMed ID: 21082296
    [No Abstract]   [Full Text] [Related]  

  • 7. Imatinib mesylate: a new pill for chronic myelogenous leukemia.
    Parmar KK; King RS
    Cancer Pract; 2001; 9(5):263-5. PubMed ID: 11879324
    [No Abstract]   [Full Text] [Related]  

  • 8. Gold standard or wrong standard?
    Oldham R; Dillman R
    Cancer Biother Radiopharm; 2004 Jun; 19(3):271-2. PubMed ID: 15285873
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of surgery and imatinib mesylate in the treatment of advanced gastrointestinal stromal tumor: a systematic review.
    Cirocchi R; Farinella E; La Mura F; Cavaliere D; Avenia N; Verdecchia GM; Giustozzi G; Noya G; Sciannameo F
    Tumori; 2010; 96(3):392-9. PubMed ID: 20845798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib for imatinib-resistant GIST.
    Joensuu H
    Lancet; 2006 Oct; 368(9544):1303-4. PubMed ID: 17046443
    [No Abstract]   [Full Text] [Related]  

  • 11. Lack of response to imatinib mesylate as second-line therapy in a patient with c-kit positive metastatic soft tissue leiomyosarcoma.
    Silvestris N; Parra HS; Angelini F; Di Cosimo S; D'Aprile M; Santoro A
    Tumori; 2005; 91(1):103. PubMed ID: 15850018
    [No Abstract]   [Full Text] [Related]  

  • 12. Imatinib mesylate.
    Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
    [No Abstract]   [Full Text] [Related]  

  • 13. [Evolution of chronic myeloid leukemia on nilotinib after failure of imatinib].
    Sawadogo S; Hien FM; Ouédraogo MS; Drabo YJ
    Pan Afr Med J; 2014; 18():142. PubMed ID: 25419280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
    Druker BJ
    Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials.
    Keill R
    Bull Am Coll Surg; 2003 May; 88(5):43. PubMed ID: 23581062
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.
    Zackova D; Klamova H; Muzik J; Cmunt E; Racil Z; Machova Polakova K; Dvorakova D; Jurcek T; Razga F; Cetkovsky P; Dusek L; Mayer J
    Leuk Lymphoma; 2013 Oct; 54(10):2310-3. PubMed ID: 23373966
    [No Abstract]   [Full Text] [Related]  

  • 17. Imatinib: as adjuvant therapy for gastrointestinal stromal tumor†: profile report.
    Sanford M; Scott LJ
    BioDrugs; 2011 Jun; 25(3):191-2. PubMed ID: 21627342
    [No Abstract]   [Full Text] [Related]  

  • 18. Imatinib mesylate as therapy for gastrointestinal stromal tumor.
    Peshwe HB; Chatni S; Basu S
    Indian J Gastroenterol; 2005; 24(4):188. PubMed ID: 16204927
    [No Abstract]   [Full Text] [Related]  

  • 19. Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels.
    Gambacorti-Passerini C; Piazza R; D'Incalci M
    Blood; 2003 Sep; 102(5):1933-4; author reply 1934-5. PubMed ID: 12930735
    [No Abstract]   [Full Text] [Related]  

  • 20. Imatinib: resisting the resistance.
    Rothberg PG
    Leuk Res; 2003 Nov; 27(11):977-8. PubMed ID: 12859989
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.